组蛋白去乙酰化酶与溴结构域联合抑制在非小细胞肺癌中的协同免疫刺激效应及治疗获益
研究评估组蛋白去乙酰化酶(HDAC)抑制剂与溴结构域抑制剂对非小细胞肺癌(NSCLC)免疫微环境的调控作用。选择性HDAC6抑制剂ricolinostat促进T细胞活化和抗原提呈细胞功能,JQ1减弱CD4+FOXP3+调节性T细胞抑制功能,两者协同促进免疫介导的肿瘤生长停滞并延长肺腺癌小鼠生存。
要点
- 选择性HDAC6抑制剂ricolinostat促进T细胞活化和抗原提呈细胞功能改善。
- 溴结构域抑制剂JQ1减弱CD4+FOXP3+调节性T细胞的抑制功能。
- JQ1与ricolinostat协同促进免疫介导的肿瘤生长停滞并延长肺腺癌小鼠生存。
核心结论
- 两种表观遗传修饰剂联合可促进T细胞介导的抗肿瘤免疫,并展示出治疗NSCLC的治疗潜力。
研究设计与样本
- 研究评估HDAC抑制剂和溴结构域抑制剂对参与免疫反应的关键细胞亚群的免疫调节特性,并分析人外周血和NSCLC肿瘤样本。
主要发现
- 选择性HDAC6抑制剂ricolinostat促进支持增强T细胞活化和改善抗原提呈细胞功能的表型变化。
- 溴结构域抑制剂JQ1减弱CD4+FOXP3+调节性T细胞的抑制功能。
- JQ1与ricolinostat协同促进免疫介导的肿瘤生长停滞,延长肺腺癌小鼠生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit. Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response. By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. The bromodomain inhibitor JQ1 attenuated CD4+FOXP3+ T regulatory cell suppressive function and synergized with ricolinostat to facilitate immune-mediated tumor growth arrest, leading to prolonged survival of mice with lung adenocarcinomas. Collectively, our findings highlight the immunomodulatory effects of two epigenetic modifiers that, together, promote T cell-mediated antitumor immunity and demonstrate their therapeutic potential for treatment of NSCLC.Significance: Selective inhibition of HDACs and bromodomain proteins modulates tumor-associated immune cells in a manner that favors improved T-cell function and reduced inhibitory cellular mechanisms. These effects facilitated robust antitumor responses in tumor-bearing mice, demonstrating the therapeutic potential of combining these epigenetic modulators for the treatment of NSCLC. Cancer Discov; 7(8); 852-67. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 783.
引用
- Adeegbe DO, Liu Y, Lizotte PH, et al. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017. PMID: 28408401. doi:10.1158/2159-8290.CD-16-1020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。